Potassium Iodide: Mechanism, Uses, Side Effects

Mechanism of action

Potassium iodide provides pharmacologic doses of stable iodine (iodide ion). When administered before or shortly after exposure to radioactive iodine isotopes, KI saturates the thyroid gland with non-radioactive iodine, competitively blocking uptake of radioactive iodine-131 and other isotopes. This protects the thyroid from radiation-induced injury and subsequent thyroid cancer.

In chronic obstructive pulmonary disease and bronchitis, potassium iodide acts as an expectorant by increasing respiratory tract secretions and reducing mucus viscosity through direct stimulation of bronchial glands. The exact mechanism remains incompletely understood but likely involves local irritation and reflex stimulation.

In hyperthyroidism, high-dose iodide acutely inhibits thyroid hormone synthesis and release through the Wolff-Chaikoff effect, where excess iodide temporarily blocks organification of iodine and suppresses thyroid peroxidase activity. This effect typically lasts 7-14 days before the thyroid escapes inhibition. Iodide also decreases thyroid gland vascularity, which is useful preoperatively in thyroidectomy for Graves disease.

Potassium iodide provides essential iodine for thyroid hormone synthesis in iodine-deficient states, supporting normal thyroid function and preventing goiter formation.

High-yield for exams

Potassium iodide blocks radioactive iodine uptake by saturating thyroid with stable iodine; most effective within 3-4 hours of exposure
Wolff-Chaikoff effect: high-dose iodide acutely inhibits thyroid hormone synthesis but thyroid typically escapes after 7-14 days
In thyroid storm preparation, give antithyroid drugs first, then KI at least 1 hour later to prevent substrate for new hormone synthesis
Jod-Basedow phenomenon: iodine-induced hyperthyroidism in patients with nodular goiter or latent Graves disease exposed to iodine loads
Itraconazole is first-line treatment for sporotrichosis; SSKI is an effective alternative when itraconazole is not tolerated
Potassium iodide can cause both hypothyroidism (Wolff-Chaikoff effect) and hyperthyroidism (Jod-Basedow phenomenon) depending on patient susceptibility
Contraindicated in dermatitis herpetiformis due to high risk of severe iodide-induced skin reactions
Lugol solution is used preoperatively to decrease thyroid vascularity and reduce surgical bleeding in thyroidectomy

Indications

Radiation emergency thyroid protection

Potassium iodide is FDA-approved for thyroid blocking in radiation emergencies involving release of radioactive iodine. It is most effective when given immediately before or within 3-4 hours after exposure. Public health authorities distribute KI to populations near nuclear facilities.

Expectorant

KI is used as an expectorant in chronic bronchitis, chronic obstructive pulmonary disease, and asthma with thick mucus production. It helps mobilize and thin bronchial secretions, though newer mucolytics have largely replaced it.

Thyrotoxicosis and preoperative preparation

High-dose potassium iodide (Lugol solution or saturated solution of potassium iodide, SSKI) is used for acute management of thyroid storm and preparation for thyroidectomy in hyperthyroid patients. It reduces thyroid hormone release and decreases gland vascularity, minimizing surgical bleeding. It is typically given 7-10 days preoperatively after antithyroid drugs have controlled hyperthyroidism.

Sporotrichosis

Itraconazole is the first-line treatment for cutaneous and lymphocutaneous sporotrichosis, a fungal infection caused by Sporothrix schenckii. Saturated solution of potassium iodide (SSKI) remains an effective alternative when itraconazole is not tolerated or contraindicated. The mechanism of antifungal activity is unclear.

Iodine deficiency

KI supplements dietary iodine in areas with endemic iodine deficiency to prevent goiter and cretinism.

Pharmacokinetics

Potassium iodide is rapidly and completely absorbed from the gastrointestinal tract after oral administration. Peak serum levels occur within 1-2 hours. Iodide distributes throughout extracellular fluid and concentrates in the thyroid gland, salivary glands, gastric mucosa, and breast tissue.

The thyroid gland normally takes up about 30% of absorbed iodide, but this uptake is blocked when pharmacologic doses saturate thyroid iodine transport. Iodide does not bind significantly to plasma proteins.

Iodide is primarily eliminated by the kidneys, with renal clearance approximating glomerular filtration rate. Smaller amounts are excreted in saliva, sweat, and breast milk. The elimination half-life is approximately 8 hours in individuals with normal renal function but is prolonged in renal impairment.

Potassium iodide crosses the placenta and is excreted in breast milk, which is clinically significant for fetal and neonatal thyroid effects.

Adverse effects

Iodism

Chronic iodide toxicity (iodism) presents with metallic taste, increased salivation, coryza, sneezing, conjunctivitis, skin rashes (acneiform or urticarial), and gastric disturbance. This typically occurs with prolonged use.

Thyroid dysfunction

Potassium iodide can cause both hypothyroidism and hyperthyroidism. The Wolff-Chaikoff effect may fail to escape in susceptible individuals, causing iodine-induced hypothyroidism, particularly in patients with underlying autoimmune thyroiditis, prior thyroid surgery, or radioactive iodine treatment. Conversely, the Jod-Basedow phenomenon describes iodine-induced hyperthyroidism in patients with multinodular goiter or latent Graves disease when exposed to iodine loads.

Fetal and neonatal goiter and hypothyroidism can occur with maternal KI use, especially with prolonged exposure.

Hypersensitivity reactions

Allergic reactions range from mild rash to severe reactions including angioedema, cutaneous and mucosal hemorrhage, serum sickness-like symptoms, and rarely, life-threatening anaphylaxis. Patients with dermatitis herpetiformis are particularly susceptible to iodide-induced skin reactions.

Gastrointestinal effects

Nausea, vomiting, epigastric pain, and diarrhea are common, particularly with high doses. Taking KI with food or milk reduces gastric irritation.

Parotid and salivary gland swelling

Sialadenitis with painful parotid swelling (iodide mumps) occasionally occurs.

Other effects

Arthralgia, eosinophilia, lymphadenopathy, and fever may occur. Potassium overload can cause hyperkalemia, particularly in patients with renal impairment or those taking potassium-sparing medications.

Contraindications and warnings

Potassium iodide is contraindicated in known hypersensitivity to iodides. Dermatitis herpetiformis is a relative contraindication due to high risk of severe cutaneous reactions.

Caution is required in patients with thyroid disorders. Pre-existing nodular thyroid disease increases risk of iodine-induced hyperthyroidism. Patients with autoimmune thyroiditis, prior thyroid surgery, or radioactive iodine treatment are at increased risk for iodine-induced hypothyroidism.

Renal impairment increases risk of hyperkalemia and prolonged iodide exposure. Use with caution and monitor electrolytes and renal function.

In pregnancy, KI crosses the placenta and can cause fetal goiter and hypothyroidism with prolonged use. However, short-term use for radiation protection is considered acceptable when the benefit outweighs risk. Neonates born to mothers receiving KI should have thyroid function monitored.

Potassium iodide is excreted in breast milk and can affect infant thyroid function. Breastfeeding infants should be monitored if the mother receives KI, though single-dose radiation protection is generally considered compatible with breastfeeding.

Patients with acute bronchitis should use KI cautiously as it may worsen cough initially.

Myotonia congenita and hypocomplementemic vasculitis are rare conditions that may be exacerbated by iodides.

Drug interactions

Lithium and potassium iodide have synergistic hypothyroid effects. Combined use increases risk of goiter and hypothyroidism. Avoid concurrent use when possible.

Potassium-sparing diuretics (spironolactone, amiloride, triamterene), ACE inhibitors, and angiotensin receptor blockers increase hyperkalemia risk when combined with potassium iodide. Monitor serum potassium levels closely.

Antithyroid drugs (methimazole, propylthiouracil) combined with potassium iodide provide additive thyroid suppression, which is therapeutically useful in preparing hyperthyroid patients for surgery. However, this increases hypothyroidism risk.

Radioactive iodine therapy for thyroid cancer or hyperthyroidism is antagonized by potassium iodide. KI should be discontinued at least 7 days before radioactive iodine administration to allow adequate thyroid uptake of the therapeutic isotope.

Thyroid medications (levothyroxine, liothyronine) may require dose adjustment in patients receiving chronic potassium iodide, as KI can alter thyroid hormone levels.

Quinidine renal elimination may be increased by potassium iodide, potentially reducing quinidine efficacy.

Clinical pearls

Potassium iodide is most effective for radiation protection when given within 3-4 hours of exposure; efficacy decreases significantly after 24 hours.

The Wolff-Chaikoff effect (iodide-induced thyroid suppression) typically lasts only 7-14 days before thyroid escape occurs, limiting KI usefulness for long-term hyperthyroidism management.

For preoperative thyroid preparation, potassium iodide should only be started after the patient is euthyroid on antithyroid drugs; starting KI in an uncontrolled hyperthyroid patient can worsen thyrotoxicosis.

Saturated solution of potassium iodide (SSKI) for sporotrichosis is given in gradually increasing doses to maximize tolerability as directed on product label.

In thyroid storm, potassium iodide should be given at least 1 hour after antithyroid drug administration to prevent iodide from being used as substrate for new thyroid hormone synthesis.

Lugol solution contains both iodine and potassium iodide, providing concentrated iodine per drop, while SSKI provides a different concentration of iodide per drop as specified on product label.

Allergic reactions to iodinated contrast media do not predict KI allergy, as contrast reactions are typically related to the organic molecule rather than iodine itself.

Taking potassium iodide with milk or food significantly reduces gastrointestinal side effects.

Chronic expectorant use of KI has largely been replaced by safer alternatives like guaifenesin and N-acetylcysteine.

Practice questions

1. A 45-year-old woman with multinodular goiter undergoes CT angiography with iodinated contrast for evaluation of chest pain. Three days later, she develops palpitations, tremor, heat intolerance, and weight loss. Vital signs show heart rate 118/min, blood pressure 145/82 mmHg, and temperature 37.8°C (100°F). Thyroid function tests reveal TSH <0.01 mIU/L (normal 0.4-4.0) and free T4 4.8 ng/dL (normal 0.8-1.8). Which of the following best explains this patient's condition?

Answer: C. This patient has Jod-Basedow phenomenon, iodine-induced hyperthyroidism occurring when patients with underlying autonomous thyroid tissue (multinodular goiter or latent Graves disease) are exposed to iodine loads such as iodinated contrast. The autonomous tissue uses the excess iodine substrate to produce excessive thyroid hormone. The Wolff-Chaikoff effect causes hypothyroidism, not hyperthyroidism, and contrast-induced thyroiditis typically presents earlier with neck pain. This is not an allergic phenomenon, and medical contrast is not radioactive.

2. A 32-year-old woman with Graves disease is scheduled for total thyroidectomy in 10 days. She has been treated with methimazole for 6 weeks and is now euthyroid. To minimize surgical bleeding, her endocrinologist prescribes Lugol solution starting today. When should the first dose of Lugol solution be administered relative to her morning methimazole dose?

Answer: C. Lugol solution (iodine/potassium iodide) should be given at least 1 hour after antithyroid drugs to prevent the iodide from serving as substrate for new thyroid hormone synthesis. Antithyroid drugs must first block thyroid peroxidase before iodide is introduced. While this specific timing is more critical in thyroid storm than in stable, euthyroid patients, it remains best practice. Methimazole should be continued alongside iodide preoperatively. The patient must be euthyroid before starting iodide to avoid worsening hyperthyroidism.

3. A 28-year-old man presents with chronic ulcerated nodules along his right arm following a rose thorn injury 6 weeks ago. The lesions follow lymphatic distribution. Tissue culture grows Sporothrix schenckii. Which of the following is the most appropriate treatment?

Answer: C. This is lymphocutaneous sporotrichosis, classically associated with rose gardening or handling sphagnum moss. Itraconazole is the first-line treatment for cutaneous and lymphocutaneous sporotrichosis. Saturated solution of potassium iodide (SSKI) is an effective alternative when itraconazole is not tolerated or contraindicated, started at low doses and gradually titrated. While fluconazole and amphotericin B have antifungal activity, they are not first-line for this indication. Amphotericin B is reserved for disseminated or severe pulmonary disease. Topical therapy is ineffective for lymphocutaneous involvement.

Frequently asked questions

How does potassium iodide work for radiation protection?

Potassium iodide saturates the thyroid gland with stable, non-radioactive iodine, competitively blocking uptake of radioactive iodine isotopes like iodine-131. When the thyroid is saturated with stable iodine, radioactive iodine cannot be absorbed and is excreted from the body, preventing radiation damage to the thyroid and reducing thyroid cancer risk. This protective effect is most effective when KI is taken immediately before or within 3-4 hours after radiation exposure.

What are the side effects of potassium iodide?

Common side effects include metallic taste, stomach upset, nausea, and skin rash. Chronic use can cause iodism (metallic taste, increased salivation, runny nose, acne-like rash). Potassium iodide can cause thyroid dysfunction, including both hypothyroidism and hyperthyroidism, depending on the patient's underlying thyroid condition. Allergic reactions ranging from mild rash to severe anaphylaxis can occur. Hyperkalemia is a risk in patients with kidney disease or those taking certain medications.

When should potassium iodide be taken for radiation emergency?

Potassium iodide should be taken as soon as possible after notification of a radiation emergency involving radioactive iodine release, ideally immediately before or within 3-4 hours of exposure. Effectiveness decreases significantly when taken more than 6 hours after exposure and is minimal after 24 hours. Public health authorities will announce when KI should be taken. Do not take KI preemptively without official guidance, as unnecessary use carries risks of thyroid dysfunction.

Can potassium iodide cause thyroid problems?

Yes, potassium iodide can cause both hypothyroidism and hyperthyroidism. High doses trigger the Wolff-Chaikoff effect, temporarily suppressing thyroid function, which can lead to hypothyroidism especially in people with autoimmune thyroiditis or prior thyroid treatment. Conversely, the Jod-Basedow phenomenon describes iodine-induced hyperthyroidism in patients with multinodular goiter or latent Graves disease. Prolonged maternal use can cause fetal goiter and hypothyroidism. For short-term radiation protection, these risks are generally acceptable.

Potassium iodide vs iodine — what is the difference?

Potassium iodide (KI) is a salt that provides iodide ion when dissolved, while elemental iodine (I₂) is the molecular form. Medically, both provide iodine but in different chemical forms. Lugol solution contains both elemental iodine and potassium iodide. For radiation protection and most medical uses, potassium iodide is preferred because it is less irritating and better tolerated than elemental iodine. Both saturate the thyroid with stable iodine, but KI is the standard formulation for thyroid blocking.

Conditions it is used for

Radiation exposure (thyroid protection)Thyroid stormHyperthyroidism (preoperative preparation)Sporotrichosis (cutaneous and lymphocutaneous)Chronic bronchitisIodine deficiencyGoiter prevention

MethimazolePropylthiouracilLevothyroxinePropranololItraconazoleGuaifenesinSodium iodide I-131Lithium

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlus WHO ATC/DDD index: R05CA02 WHO ATC/DDD index: S01XA04

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.

Potassium iodide